COMPANY PROFILE

Evergreen Theragnostics

Explore full profile

Contract development and manufacturing of therapeutic radiopharmaceuticals

Jersey City, United StatesFounded 2019Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Evergreen Theragnostics

Evergreen Theragnostics is a specialized company focused on the manufacturing, development, and distribution of therapeutic and diagnostic radiopharmaceuticals. The company operates in the biopharmaceutical sector, catering to clients involved in clinical trials and commercial radiopharmaceutical applications. Evergreen Theragnostics serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The business model revolves around providing a broad range of services for centrally distributed radiopharmaceuticals, from early-phase clinical trials (Phase 0) through to full commercialization. Revenue is generated through service contracts, manufacturing agreements, and distribution deals. The company has established itself as a leader in the North American market, known for its unrivaled expertise and state-of-the-art production facilities. Evergreen Theragnostics recently completed a $19 million Series A capital raise, which will support the expansion of its manufacturing capabilities and further development of its service offerings.

Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2019
Headquarters: Jersey City, United States
Employees: 60
Open positions: None listed
Dealroom signal: 60.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Health Diagnostics, Biotech and Pharma, Hard Tech, Radiopharmaceuticals, ogr torino, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jan 2025	$250M	—	Lantheus Holdings	↗
GRANTOther financing	Apr 2024	$26M	—	Petrichor · LIFTT	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Evergreen Theragnostics website traffic

Latest recorded traffic for Evergreen Theragnostics is 910 monthly website visits, down 52.1% over the last three months. Evergreen Theragnostics's team declined 38.1% over the past year.

Latest monthly visits910 3-month web change-52.1% 1-year team growth-38.1%

Monthly website visitsOct 2020–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBivisionA biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT)	Jing'an District, China	Operational	—	$96M	$220M
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
NANanoTheaNanoThea \| Radiopharmaceuticals	Warsaw, Poland	Operational
PEPET-TechnologyFederal network of medical centers for the diagnosis and treatment of cancer and the production of radiopharmaceuticals	Moscow, Russia	Acquired
TITriad IsotopesCompany that specializes in serving radiopharmaceuticals based nuclear medicine across worldwide facilities	Orlando, United States	Operational
NMNorthstar Nuclear MedicineProviding patients global access to game-changing radiopharmaceuticals	Madison, United States	Operational
NRNucleus RadioPharmaTransforming lives with radiopharmaceuticals by leveraging world class clinical, development, manufacturing, and supply chain expertise	Davidson, United States	Operational
NUNuclidiumSetting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis	Basel, Switzerland	Operational